Mild Cognitive Impairment - Pipeline Review, H1 2019

Publisher Name :
Date: 23-May-2019
No. of pages: 131
Inquire Before Buying

Mild Cognitive Impairment - Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Pipeline Review, H1 2019, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape.

Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety and apathy. Risk factors include diabetes, high blood pressure, and depression, smoking and elevated cholesterol.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mild Cognitive Impairment - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 9, 3, 1, 12 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Mild Cognitive Impairment (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Mild Cognitive Impairment (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Mild Cognitive Impairment (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Mild Cognitive Impairment - Pipeline Review, H1 2019

Table of Contents
Introduction
Mild Cognitive Impairment - Overview
Mild Cognitive Impairment - Therapeutics Development
Mild Cognitive Impairment - Therapeutics Assessment
Mild Cognitive Impairment - Companies Involved in Therapeutics Development
Mild Cognitive Impairment - Drug Profiles
Mild Cognitive Impairment - Dormant Projects
Mild Cognitive Impairment - Discontinued Products
Mild Cognitive Impairment - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Mild Cognitive Impairment, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Target, H1 2019 (Contd..1), H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Mild Cognitive Impairment - Pipeline by AbbVie Inc, H1 2019
Mild Cognitive Impairment - Pipeline by Addex Therapeutics Ltd, H1 2019
Mild Cognitive Impairment - Pipeline by AgeneBio Inc, H1 2019
Mild Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd, H1 2019
Mild Cognitive Impairment - Pipeline by Biogen Inc, H1 2019
Mild Cognitive Impairment - Pipeline by CereSpir Inc, H1 2019
Mild Cognitive Impairment - Pipeline by CuraSen Therapeutics Inc, H1 2019
Mild Cognitive Impairment - Pipeline by Eisai Co Ltd, H1 2019
Mild Cognitive Impairment - Pipeline by Eli Lilly and Co, H1 2019
Mild Cognitive Impairment - Pipeline by Fujifilm Toyama Chemical Co Ltd, H1 2019
Mild Cognitive Impairment - Pipeline by Merck & Co Inc, H1 2019
Mild Cognitive Impairment - Pipeline by Neuron Biopharma SA, H1 2019
Mild Cognitive Impairment - Pipeline by Octapharma AG, H1 2019
Mild Cognitive Impairment - Pipeline by Pfizer Inc, H1 2019
Mild Cognitive Impairment - Pipeline by Protekt Therapeutics Ltd, H1 2019
Mild Cognitive Impairment - Pipeline by Sage Therapeutics Inc, H1 2019
Mild Cognitive Impairment - Pipeline by SBI Pharmaceuticals Co Ltd, H1 2019
Mild Cognitive Impairment - Pipeline by Therapix Biosciences Ltd, H1 2019
Mild Cognitive Impairment - Dormant Projects, H1 2019
Mild Cognitive Impairment - Dormant Projects, H1 2019 (Contd..1), H1 2019
Mild Cognitive Impairment - Discontinued Products, H1 2019

List of Figures
Number of Products under Development for Mild Cognitive Impairment, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019
  • Dementia Associated With Alzheimer's Disease - Global Clinical Trials Review, H2, 2020
    Published: 23-Dec-2020        Price: US 2500 Onwards        Pages: 304
    Dementia Associated With Alzheimer's Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Dementia Associated With Alzheimer's Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Dementia Associated With Alzheimer's Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Dementia Associated With Alzheimer's Disease. Report includes an overview of trial number......
  • Social Anxiety Disorder (SAD Social Phobia) Disease - Global Clinical Trials Review, H2, 2020
    Published: 22-Dec-2020        Price: US 2500 Onwards        Pages: 175
    Social Anxiety Disorder (SAD Social Phobia) Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Social Anxiety Disorder (SAD Social Phobia) Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Social Anxiety Disorder (SAD Social Phobia) Clinical trials scenario. This report provides top line data relating to the clinical trials on Social Anxiety Disorder (SAD Social Phobia). Report includes an overview of ......
  • Cluster Headache Syndrome (Cluster Headache) Disease - Global Clinical Trials Review, H2, 2020
    Published: 16-Dec-2020        Price: US 2500 Onwards        Pages: 80
    Cluster Headache Syndrome (Cluster Headache) Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Cluster Headache Syndrome (Cluster Headache) Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Cluster Headache Syndrome (Cluster Headache) Clinical trials scenario. This report provides top line data relating to the clinical trials on Cluster Headache Syndrome (Cluster Headache). Report includes an overview......
  • Global Drugs of Nervous System Market Research Report with Opportunities and Strategies to Boost Growth- COVID-19 Impact and Recovery
    Published: 15-Dec-2020        Price: US 3500 Onwards        Pages: 130
    Drugs of Nervous System are drugs used for the treatment of diseases affecting the brain or spinal cord such as epilepsy, Parkinson's disease, Alzheimer's disease, depression, anxiety and bipolar disorders. Epilepsy is a chronic brain disorder characterized by recurring seizures. Parkinson's disease is a degenerative CNS disorder associated with symptoms including tremor, rigidity, akinesia and bradykinesia. Based on the Drugs of Nervous System market development status, competitive lands......
  • Tourette Syndrome Disease - Global Clinical Trials Review, H2, 2020
    Published: 01-Dec-2020        Price: US 2500 Onwards        Pages: 106
    Tourette Syndrome Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Tourette Syndrome Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Tourette Syndrome Clinical trials scenario. This report provides top line data relating to the clinical trials on Tourette Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offer......
  • Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2020
    Published: 30-Nov-2020        Price: US 2500 Onwards        Pages: 868
    Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2020, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape. Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathop......
  • Insomnia - Pipeline Review, H2 2020
    Published: 30-Nov-2020        Price: US 2000 Onwards        Pages: 164
    Insomnia - Pipeline Review, H2 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Insomnia - Pipeline Review, H2 2020, provides an overview of the Insomnia (Central Nervous System) pipeline landscape. Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches and distre......
  • Cancer Pain - Pipeline Review, H2 2020
    Published: 30-Nov-2020        Price: US 2000 Onwards        Pages: 154
    Cancer Pain - Pipeline Review, H2 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain - Pipeline Review, H2 2020, provides an overview of the Cancer Pain (Central Nervous System) pipeline landscape. Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatment......
  • Migraine - Pipeline Review, H2 2020
    Published: 30-Nov-2020        Price: US 2000 Onwards        Pages: 342
    Migraine - Pipeline Review, H2 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Migraine - Pipeline Review, H2 2020, provides an overview of the Migraine (Central Nervous System) pipeline landscape. Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with n......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs